Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ESC 2026
From trials to treatment: real-world vericiguat initiation and residual risk in Germany
- In patients with HFrEF but no recent WHF, the VICTOR trial (NCT05093933) showed no statistically significant benefit with vericiguat versus placebo in the primary endpoint.
- We investigated clinical characteristics and outcomes in a real-world cohort of patients treated with vericiguat in routine care.
- This retrospective cohort study used anonymised claims data from the German InGef Health Research Database (approximately 10 million insured individuals).
- In German routine care, vericiguat is initiated predominantly in VICTORIA-like patients but also in a substantial VICTOR-like minority, including patients with recent ODI.
- ODI may represent an outpatient marker of WHF risk comparable to recent HHF, even among ostensibly stable patients.
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
